Form 4: Ultragenyx CMO Reports Routine Stock Transactions

Ultragenyx Pharmaceutical Inc.'s EVP and Chief Medical Officer, Eric Crombez, reported the conversion of performance stock units and subsequent sale of shares for tax withholdings.

Summary

• EVP and Chief Medical Officer Eric Crombez acquired 11,643 shares of Ultragenyx Pharmaceutical Inc. common stock on March 1, 2026, through the conversion of previously granted performance stock units.
• Following this acquisition, Crombez beneficially owned 83,173 shares.
• On March 2, 2026, Crombez sold 7,029 shares of common stock at a weighted average price of $22.80 per share to cover tax withholdings related to the vesting of Restricted Stock Units (RSUs).
• The shares sold ranged in price from $22.54 to $23.11.
• After these transactions, Crombez's direct beneficial ownership stands at 76,301 shares.
• This total includes 157 shares acquired on October 30, 2025, via the Company's Amended and Restated Employee Stock Purchase Plan and previously reported RSU shares subject to vesting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. The conversion of performance units is a positive signal of goal achievement, while the tax-related sale is a routine, non-discretionary event.

Positives

• The conversion of 11,643 performance stock units indicates that performance metrics were certified, suggesting the company met certain internal goals.

Negatives

• The sale of 7,029 shares, even if for tax withholdings, reduces the insider's direct ownership in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to compensation and tax obligations, are common in the biotechnology and pharmaceutical sectors. The conversion of performance stock units suggests the achievement of specific corporate milestones, which is generally viewed positively, while the subsequent sale for tax purposes is a routine event and not typically indicative of a change in management's long-term view of the company.

Comparison to Industry Standards

• The conversion of performance stock units is a standard practice in executive compensation across the biotech industry, aligning executive incentives with company performance. For example, similar compensation structures are observed at companies like Regeneron Pharmaceuticals (REGN) and Vertex Pharmaceuticals (VRTX).
• The sale of shares to cover tax obligations upon RSU vesting is a common and expected event for executives receiving equity compensation, consistent with practices at peer companies such as Amgen (AMGN) and Gilead Sciences (GILD).

Stakeholder Impact

• Shareholders: The conversion of performance units could be seen as a positive indicator of management achieving targets, while the tax-related sale is a routine event with minimal impact on overall share structure.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) indicates ongoing employee equity participation programs.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of performance stock units and subsequent sale of shares for tax purposes. While the conversion of performance units suggests the achievement of internal company goals, the sale for tax withholdings is a non-discretionary event and does not reflect a change in the insider's investment sentiment. Therefore, this filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, as it primarily reflects standard compensation practices rather than a strategic investment decision.

Keywords

Ultragenyx Pharmaceutical, RARE, Insider Trading, Form 4, Stock Transaction, Executive Compensation, Performance Stock Units, RSU Vesting, Eric Crombez